ASAH1 and prostate carcinoma: More importantly, ASAH1 inhibitors have been proposed as radiosensitizers, on the basis of studies that illustrated a greater suppression of the growth of U87 and prostate cancer xenografts when treated with both conventional radiation therapy and ASAH1 inhibitors [87,98].